Blog

National regulations, pharmaceutical companies who sample compliance?


Release time:

2024-10-25

DST teacher recently in the audit process, found that some customers of the sampling work by the QA to be responsible for, some pharmaceutical companies by the QC sampling, so who is responsible for the sampling, who is responsible for the authorization is appropriate? Today we will come to discuss the issue of sampling, let us start from the regulations, look at the relevant provisions.

DST teacher recently in the audit process, found that some customers of the sampling work by the QA to be responsible for, some pharmaceutical companies by the QC sampling, so who is responsible for the sampling, who is responsible for the authorization is appropriate? Today we will come to discuss the issue of sampling, let us start from the regulations, look at the relevant provisions.

NMPA 2010 GMPArticle 12 Basic requirements for quality control:

(III), authorized personnel shall take samples of raw and auxiliary materials, packaging materials, intermediate products, products to be packaged and finished products in accordance with the prescribed methods.

NMPA 2010 GMPArticle 222 Sampling shall meet at least the following requirements:

Personnel of the (I) Quality Management Department have the right to enter the production area and storage area for sampling and investigation;

The (II) shall be sampled in accordance with approved operating procedures, which shall specify in detail:

1. Authorized samplers;......

FDA 21CFR Part211

Sec. 211.42 Design and construction features-Design and Build Requirements

(c)(1) Receipt, identification, storage, and withholding from use of components, drug product containers, closures, and labeling, pending the appropriate sampling, testing examination by the quality control unit before release for manufacturing or packaging.

Before release to production or packaging, the quality control department shall adopt appropriate sampling methods and testing to receive, identify, store and disable raw and auxiliary materials, drug containers, seals and labels.

EU GMP:

Quality Control Quality Control

1.9 Quality Control is that part of Good Manufacturing Practice which is concerned with sampling, specifications and testing, and with the organization, documentation and released for use, nor products released for sale or supply, until their quality has been judged to be satisfactory. The basic requirements of Quality Control are that:质量控制是GMP的一部分,涉及取样、质量标准、检验、同样也涉及组织机构、文件和放行规程,以保证切实执行了必要的相关检验,并且确保物料或产品被判定符合要求之前不被放行使用或销售。质量控制的基本要求是:

(ⅰ) Adequate facilities, trained personnel and approved procedures are available for sampling and testing starting materials, packaging materials, intermediate, bulk, and finished products, and where appropriate for monitoring environmental conditions for monitoring for GMP purposes;

Adequate facilities, trained personnel and approved procedures for sampling and inspection of starting materials, packaging materials, intermediates, semi-finished products and finished products, as well as environmental monitoring required by GMP;

(ⅱ) Samples of starting materials, packaging materials,intermediate products, bulk products and finished products are taken by approved personnel and methods.

Sampling of starting materials, packaging materials, intermediate products, semi-finished products and finished products by approved personnel according to approved methods.

6.4 Quality Control personnel should have access to production areas for sampling and investigation as appropriate.

Quality control personnel should have access to the production area for sampling and investigation.

PIC/S GMP

2.8 The head of Quality Control generally has the following responsibilities:

The Quality Control Responsible generally has the following responsibilities:

(ⅲ) To ensure that all necessary testing is carried out and the associated records evaluated. Approve quality standards, sampling methods, inspection methods and other quality control procedures.

6.2 The Quality Control Department as a whole will also have other duties,such as to establish,validate and implement all quality control procedures,oversee the control of the reference and/or retention samples of materials and products when applicable,ensure the correct labeling of containers of materials and products,ensure the monitoring of the stability of the products,participate in the investigation of complaints related to the quality of the product, etc. All these operations should be carried out in accordance with written procedures and, where necessary, recorded.

The entire Quality Control Department will also have other responsibilities, such as establishing, verifying and implementing all quality control procedures, supervising the control of reference and/or retention of materials and products, ensuring correct labeling of materials and product containers, ensuring product stability inspections, and participating in product quality related complaints investigations.

6.4 Quality Control personnel should have access to production areas for sampling and investigation as appropriate.

Quality control personnel shall have access to the production area for sampling and investigation.

WHO GMP

17.3 Each manufacturer should have a QC function. The QC function should be independent of other departments and under the authority of a person with appropriate qualification and experience. Adequate resources must be available to ensure that all the QC arrangements are effectively and reliably carried out. The basic requirements for QC are as follows:

Each manufacturer should have a quality control department. The quality control department should be independent of other departments and managed by personnel with appropriate qualifications and experience. Adequate resources must be provided to ensure the effective and reliable implementation of all quality control tasks. The basic requirements for the quality control department are as follows:

(a)Adequate facilities, trained personnel and approved procedures must be available for sampling, inspecting, and testing materials, packaging materials, and intermediate, bulk, and finished products, and where appropriate for monitoring environmental conditions for GMP purposes;

Adequate facilities, trained personnel and approved procedures should be available to sample, review and test raw materials, packaging materials, intermediates, products to be packaged and finished products, and monitor environmental conditions as appropriate to meet GMP requirements;

(b)Samples of starting materials, packaging materials, intermediate products, bulk products and finished products must be Quality Control departments approved personnel.

The sampling of raw materials, packaging materials, intermediates, products to be packaged and finished products must be completed by personnel approved by the quality control department according to the specified sampling method.

To sum up, in addition to China's 2010 version of GMP regulations, which are sampled by the quality management department (QA or QC), the regulations of other major regulatory agencies are more likely to be done by the quality control department, including sampling for environmental monitoring.

From the perspective of QA, QA personnel are responsible for the supervision and maintenance of the whole quality management system. QA sampling can better ensure that the sampling process conforms to established procedures and specifications, and that sampling is representative and fair. QA has the advantage of overall planning and coordination of sampling, and can grasp the timing, frequency and method of sampling from the macro level to ensure the accuracy of subsequent quality assessment. They pay more attention to the compliance of the process and the guarantee of the quality system.

However, QC personnel also have a unique expertise in sampling. QC mainly focuses on the specific detection and analysis of samples, and they have a deep understanding and mastery of sampling techniques and requirements. QC sampling can accurately obtain the required samples according to the detection purpose and method, and ensure the reliability of the detection results. QC excels in the detailed operation of sampling and in the targeting of specific test items.

In fact, whether it is QA sampling or QC sampling, the goal is to meet the strict requirements of GMP. Ideally, the two should work closely together to form a synergy. QA ensures the standardization and comprehensiveness of sampling, while QC ensures the professionalism and accuracy of sampling.

In a perfect quality management system of pharmaceutical enterprises, the responsibilities and authorities of QA and QC in sampling work should be clearly defined, and a clear workflow and communication mechanism should be established. Only in this way can the reliability and stability of product quality be improved to the greatest extent while ensuring that the sampling meets the GMP requirements.

In short, both QA sampling and QC sampling have their important significance and value, and one cannot simply judge which one is more in line with GMP requirements. Together, they contribute to the quality assurance of pharmaceutical companies and complement each other to ensure that safe and effective medicines are produced.

The author believes that the responsibility of sampling should be attributed to the quality control department. Sampling and inspection are professional and technical work. However, sampling has a large amount of work and can be authorized to be carried out by qualified personnel. For example, QA or production personnel should be authorized to carry out sampling of intermediate process samples and environmental monitoring, but they should be properly trained and QC should issue corresponding power of attorney. In addition, QC other responsibilities should also include: inspection, sample retention and stability inspection. How do you look at the responsibility of sampling? Please leave a message in the comment area.

Key words:


Related Blog


CDE: Notice on Trial Submission of Electronic Application Data for Drug Registration by Network Transmission

Durst DST Regulation Group, noting that on July 1, 2024, the Drug Evaluation Center of the State Drug Administration (hereinafter referred to as CDE) issued a trial notice on the submission of electronic application materials for drug registration by network transmission. Starting from July 1, 2024, the trial work on the network transmission of electronic application materials for drug registration will be started, and applicants can submit electronic application materials for drug registration through network transmission. There is also an attachment: the reservation for network transmission of electronic declaration materials and the description of operation steps, which is convenient to guide everyone to submit electronic declaration materials.

2024-07-05

Good news! Durst customer Sichuan Huiyu injection products successfully went to sea in the United States!

Recently, after the products of DST DST customers Sichuan well-known pharmaceutical companies passed PAI inspection in November 2023, they were officially approved in December. In June 2024, they officially sent several batches of products to enter the US market. This exciting news came at the time of the third FDA project audit of the client again. The customer is located in Neijiang City, Sichuan Province, an ancient city between Chengdu and Chongqing. The success of Huiyu Pharmaceutical has made this city more attractive to pharmaceutical people! Once again, congratulations to the customer products officially go to sea! The entry of products into the US market shows that DST customers have been strictly implementing quality management according to high standards, continuously optimizing production processes, and producing more high-quality products higher than national standards.

2024-07-05

Good news! Durst customer Sichuan Huiyu injection products successfully went to sea in the United States!

Recently, after the products of DST DST customers Sichuan well-known pharmaceutical companies passed PAI inspection in November 2023, they were officially approved in December. In June 2024, they officially sent several batches of products to enter the US market. This exciting news came at the time of the third FDA project audit of the client again. The customer is located in Neijiang City, Sichuan Province, an ancient city between Chengdu and Chongqing. The success of Huiyu Pharmaceutical has made this city more attractive to pharmaceutical people! Once again, congratulations to the customer products officially go to sea! The entry of products into the US market shows that DST customers have been strictly implementing quality management according to high standards, continuously optimizing production processes, and producing more high-quality products higher than national standards.

2024-07-05

Argument! Hengrui Warning Letter, Is It FDA's Political Sanction?

Tieguai Liu saw many posts about whether there were political factors in Hengrui's warning letter. Today, Tieguai Liu will discuss this matter with everyone's concerns. First of all, we are very sensitive to see that the "first brother" of China's pharmaceutical industry has received a warning letter from the FDA of the United States. For today's Sino-US environment, we naturally think of the FDA's sanctions against the first brother due to the influence of US politics. It is completely understandable from everyone's interpretation. The following Tieguai Liu will discuss with you from both positive and negative dimensions:

2024-10-25

Please collect the sea enterprises! Names and Websites of National and Regional Food and Drug Administration in Southeast Asia (Encyclopedia)

Durst DST continues to pay attention to the drug regulatory policies of countries around the world to help companies go to sea, and the following is the drug regulatory situation in Southeast Asian countries and regions.

2024-10-25